D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 172 Citations 154,294 666 World Ranking 172 National Ranking 117

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

The scientist’s investigation covers issues in Internal medicine, Cancer research, Oncology, Cancer and Trastuzumab. Many of his studies involve connections with topics such as Surgery and Internal medicine. His research integrates issues of Epidermal growth factor receptor, Gefitinib, Immunology and PI3K/AKT/mTOR pathway, Signal transduction in his study of Cancer research.

The various areas that José Baselga examines in his Oncology study include Neoadjuvant therapy, Regimen and Chemotherapy, Phases of clinical research. His research in Cancer intersects with topics in Endocrinology and Bioinformatics. His Trastuzumab research incorporates elements of Loading dose and Pharmacology.

His most cited work include:

  • Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 (8878 citations)
  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (4015 citations)
  • Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck (3893 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Oncology, Breast cancer, Cancer and Cancer research. José Baselga interconnects Gastroenterology and Surgery in the investigation of issues within Internal medicine. The concepts of his Oncology study are interwoven with issues in Clinical endpoint, Clinical trial, Phases of clinical research and Hazard ratio.

His work in Breast cancer addresses subjects such as Paclitaxel, which are connected to disciplines such as Doxorubicin. His studies in Cancer integrate themes in fields like Pharmacokinetics, Pharmacodynamics, Bioinformatics, Pharmacology and Pathology. His work carried out in the field of Cancer research brings together such families of science as Epidermal growth factor receptor, Tyrosine kinase, Immunology, Receptor tyrosine kinase and PI3K/AKT/mTOR pathway.

He most often published in these fields:

  • Internal medicine (56.96%)
  • Oncology (43.95%)
  • Breast cancer (35.11%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (56.96%)
  • Oncology (43.95%)
  • Breast cancer (35.11%)

In recent papers he was focusing on the following fields of study:

José Baselga spends much of his time researching Internal medicine, Oncology, Breast cancer, Cancer research and Cancer. In his study, Adjuvant therapy and Buparlisib is inextricably linked to Placebo, which falls within the broad field of Internal medicine. His Oncology study integrates concerns from other disciplines, such as Surgery, Metastatic breast cancer, Paclitaxel, Clinical endpoint and Cohort.

While the research belongs to areas of Cancer research, José Baselga spends his time largely on the problem of PI3K/AKT/mTOR pathway, intersecting his research to questions surrounding Protein kinase B. His Cancer research is multidisciplinary, incorporating elements of Gastroenterology, Tolerability and Everolimus. José Baselga has researched Trastuzumab in several fields, including Neoadjuvant therapy and Hazard ratio.

Between 2016 and 2021, his most popular works were:

  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients (1320 citations)
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (515 citations)
  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (362 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

José Baselga mainly investigates Internal medicine, Oncology, Breast cancer, Cancer research and Cancer. The Internal medicine study combines topics in areas such as Placebo and Surgery. His Oncology research includes elements of Chemotherapy, Trastuzumab, Clinical endpoint, Poor prognosis and Cohort.

His Trastuzumab research is multidisciplinary, relying on both Survival rate and Neoadjuvant therapy. José Baselga interconnects Biomarker and Receptor, Receptor tyrosine kinase in the investigation of issues within Breast cancer. His Cancer research research is multidisciplinary, incorporating perspectives in Cell, Cell growth, Mutation, Allele and PI3K/AKT/mTOR pathway.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon;Brian Leyland-Jones;Steven Shak;Hank Fuchs.
The New England Journal of Medicine (2001)

12234 Citations

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch.
The New England Journal of Medicine (2005)

5725 Citations

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

James A. Bonner;Paul M. Harari;Jordi Giralt;Nozar Azarnia.
The New England Journal of Medicine (2006)

5559 Citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura.
Journal of Clinical Oncology (2003)

3786 Citations

The landscape of somatic copy-number alteration across human cancers

Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei.
Nature (2010)

2993 Citations

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma;David Miles;Luca Gianni;Ian E. Krop.
The New England Journal of Medicine (2012)

2929 Citations

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga;Mario Campone;Martine Piccart;Howard A. Burris.
The New England Journal of Medicine (2012)

2777 Citations

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Kathryn E. O'Reilly;Fredi Rojo;Qing Bai She;David Solit.
Cancer Research (2006)

2687 Citations

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga;Javier Cortés;Sung-Bae Kim;Seock-Ah Im.
The New England Journal of Medicine (2012)

2461 Citations

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta.
The Lancet (2014)

2460 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing José Baselga

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 204

Matthew Meyerson

Matthew Meyerson

Harvard University

Publications: 200

Gordon B. Mills

Gordon B. Mills

Oregon Health & Science University

Publications: 195

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 181

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 167

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 159

Fortunato Ciardiello

Fortunato Ciardiello

University of Campania "Luigi Vanvitelli"

Publications: 159

Carlos L. Arteaga

Carlos L. Arteaga

The University of Texas Southwestern Medical Center

Publications: 157

Josep Tabernero

Josep Tabernero

Vall d´Hebron Institute of Oncology

Publications: 155

David B. Solit

David B. Solit

Memorial Sloan Kettering Cancer Center

Publications: 152

Jorge S. Reis-Filho

Jorge S. Reis-Filho

Memorial Sloan Kettering Cancer Center

Publications: 142

Rameen Beroukhim

Rameen Beroukhim

Harvard University

Publications: 140

Funda Meric-Bernstam

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

Publications: 139

Fabrice Andre

Fabrice Andre

Institut Gustave Roussy

Publications: 138

Javier Cortes

Javier Cortes

Vall d'Hebron Hospital Universitari

Publications: 136

Razelle Kurzrock

Razelle Kurzrock

Medical College of Wisconsin

Publications: 135

Something went wrong. Please try again later.